NO995469D0 - Fremgangsmåte til behandling av mentale sykdommer hos pattedyr og en sammensetning derfor - Google Patents

Fremgangsmåte til behandling av mentale sykdommer hos pattedyr og en sammensetning derfor

Info

Publication number
NO995469D0
NO995469D0 NO995469A NO995469A NO995469D0 NO 995469 D0 NO995469 D0 NO 995469D0 NO 995469 A NO995469 A NO 995469A NO 995469 A NO995469 A NO 995469A NO 995469 D0 NO995469 D0 NO 995469D0
Authority
NO
Norway
Prior art keywords
mammals
treatment
composition
mental disorders
mental
Prior art date
Application number
NO995469A
Other languages
English (en)
Other versions
NO995469L (no
Inventor
Antti Haapalinna
Timo Viitamaa
Jukka Sallinen
Mika Scheinin
Juha-Matti Savola
Original Assignee
Antti Haapalinna
Timo Viitamaa
Jukka Sallinen
Mika Scheinin
Savola Juha Matti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antti Haapalinna, Timo Viitamaa, Jukka Sallinen, Mika Scheinin, Savola Juha Matti filed Critical Antti Haapalinna
Publication of NO995469L publication Critical patent/NO995469L/no
Publication of NO995469D0 publication Critical patent/NO995469D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO995469A 1997-05-12 1999-11-08 Fremgangsmåte til behandling av mentale sykdommer hos pattedyr og en sammensetning derfor NO995469D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/854,730 US5902807A (en) 1997-05-12 1997-05-12 Method for the treatment of mental illness in mammals and a composition therefor
PCT/FI1998/000398 WO1998051310A1 (en) 1997-05-12 1998-05-11 A method for the treatment of mental illness in mammals and a composition therefor

Publications (2)

Publication Number Publication Date
NO995469L NO995469L (no) 1999-11-08
NO995469D0 true NO995469D0 (no) 1999-11-08

Family

ID=25319419

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995469A NO995469D0 (no) 1997-05-12 1999-11-08 Fremgangsmåte til behandling av mentale sykdommer hos pattedyr og en sammensetning derfor

Country Status (12)

Country Link
US (1) US5902807A (no)
EP (1) EP1003518A1 (no)
JP (1) JP2001524979A (no)
AU (1) AU744096B2 (no)
BR (1) BR9808784A (no)
CA (1) CA2288650C (no)
EE (1) EE03667B1 (no)
HU (1) HUP0002346A3 (no)
NO (1) NO995469D0 (no)
PL (1) PL336771A1 (no)
SK (1) SK154199A3 (no)
WO (1) WO1998051310A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
WO2003082825A1 (en) * 2002-04-03 2003-10-09 Orion Corporation Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
ATE374773T1 (de) * 2002-04-03 2007-10-15 Orion Corp Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
WO2004028529A1 (en) * 2002-09-24 2004-04-08 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
KR101430214B1 (ko) * 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 신경 재생제
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤

Also Published As

Publication number Publication date
AU744096B2 (en) 2002-02-14
EE9900561A (et) 2000-06-15
PL336771A1 (en) 2000-07-17
WO1998051310A1 (en) 1998-11-19
CA2288650A1 (en) 1998-11-19
HUP0002346A3 (en) 2001-09-28
EE03667B1 (et) 2002-04-15
EP1003518A1 (en) 2000-05-31
NO995469L (no) 1999-11-08
JP2001524979A (ja) 2001-12-04
CA2288650C (en) 2007-09-25
SK154199A3 (en) 2001-01-18
AU7433498A (en) 1998-12-08
HUP0002346A1 (hu) 2001-05-28
BR9808784A (pt) 2000-08-01
US5902807A (en) 1999-05-11

Similar Documents

Publication Publication Date Title
NO996483D0 (no) Imidazopyrimidiner og imidazopyridiner for behandling av neurologiske forstyrrelser
NO971236D0 (no) Flytende anordning og fremgangsmåte for fremstilling av anordningen
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO984031L (no) Bµreelement og fremgangsmÕte for fremstilling av samme
GB2322920B (en) Common rail and method of manufacturing the same
GB2322922B (en) Common rail and method of manufacturing the same
NO20002846D0 (no) Inhaleringsanordning og fremgangsmÕte ved samme
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
GB2322921B (en) Common rail and method of manufacturing the same
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
DE69816946D1 (de) Druckkompensationvorrichtung und Druckkompensationverfahren
NO985484D0 (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
NO995469L (no) Fremgangsmåte til behandling av mentale sykdommer hos pattedyr og en sammensetning derfor
IS4466A (is) Samsetning og meðhöndlun fyrir heila- og mænusigg
NO982265D0 (no) Diagnostikk for og mediatoter for inflammatoriske forstyrrelser
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
FI980246A (fi) Menetelmä keittimen käyttämiseksi ja keitin
NO983641D0 (no) Fremgangsmåte til behandling og farmasöytisk preparat
NO991382L (no) Mellomprodukter og fremgangsmÕte for fremstilling av olanzapin
NO20014674D0 (no) Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
ATE216063T1 (de) Halbleiterbrückenzünder und herstellungsverfahren dafür
NO972426D0 (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
EP0860883A4 (en) TRANSISTOR AND MANUFACTURING METHOD THEREOF
BR9509688A (pt) Composto e composição farmacêutica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application